Innovent Biologics, Inc. (OTCMKTS:IVBXF) Sees Significant Decrease in Short Interest

by · The Markets Daily

Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) saw a large decrease in short interest in the month of October. As of October 15th, there was short interest totaling 13,000 shares, a decrease of 93.3% from the September 30th total of 194,477 shares. Based on an average daily volume of 6,323 shares, the days-to-cover ratio is currently 2.1 days.

Innovent Biologics Price Performance

IVBXF stock traded down $0.90 during mid-day trading on Monday, reaching $10.65. The company had a trading volume of 1,620 shares, compared to its average volume of 3,715. The firm has a fifty day simple moving average of $12.49 and a 200 day simple moving average of $11.23. Innovent Biologics has a fifty-two week low of $9.10 and a fifty-two week high of $15.01.

About Innovent Biologics

(Get Free Report)

Innovent Biologics, Inc is a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of medicines for cancer, autoimmune diseases and metabolic disorders. The company develops biologic therapies, including monoclonal antibodies, antibody-drug conjugates and other advanced treatments, with the goal of providing innovative and more accessible medicines.

Its marketed portfolio includes sintilimab, an immunotherapy developed in collaboration with Eli Lilly and marketed in China under the brand name Tyvyt, as well as biosimilar and biologic products for oncology and immune-related conditions.

See Also